# Secretin in Ex-situ Liver Perfusion

> **NCT07651748** · PHASE1,PHASE2 · ENROLLING_BY_INVITATION · sponsor: **Erasmus Medical Center** · enrollment: 20 (estimated)

## Conditions studied

- Liver Transplantation

## Interventions

- **DRUG:** Secretin administration during ex-situ liver machine perfusion

## Key facts

- **NCT ID:** NCT07651748
- **Lead sponsor:** Erasmus Medical Center
- **Sponsor class:** OTHER
- **Phase:** PHASE1,PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** ENROLLING_BY_INVITATION
- **Start date:** 2025-04-26
- **Primary completion:** 2026-06
- **Final completion:** 2026-10
- **Target enrollment:** 20 (ESTIMATED)
- **Last updated:** 2026-06-16


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT07651748

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT07651748, "Secretin in Ex-situ Liver Perfusion". Retrieved via MORVS 2026-10-20 from https://api.morvs.ai/clinical/NCT07651748. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*